Sugammadex v.s. Neostigmine/Glycopyrrolate

NACompletedINTERVENTIONAL

Enrollment

124

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

June 12, 2025

Study Completion Date

August 12, 2025

Conditions

Head and Neck SurgeryChronic SinusitisChronic Otitis MediaLaryngeal Disease

Interventions

DRUG

Group S: sugammadex injection

Reversal agent: sugammadex

DRUG

Group N: neostigmine/glycopyrrolate

Reversal agent: glycopyrrolate and neostigmine

Trial Locations (1)

National Taiwan University Hospital, Taipei

All Listed Sponsors

lead

National Taiwan University Hospital

OTHER

NCT06398899 - Sugammadex v.s. Neostigmine/Glycopyrrolate | Biotech Hunter | Biotech Hunter